Maravai LifeSciences Holdings, Inc.
MRVI US
MRVI USMaravai LifeSciences Holdings, Inc.
United States Composite7.07
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- Full Time Employees
- 670
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10770 Wateridge Circle San Diego CA United States 92121
- IPO Date
- Nov 20, 2020
- Website
- www.maravai.com
- Business
- Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Company News
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
Steven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc
Maravai (MRVI) Advances in RNA Research With New Collaboration
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2024 Earnings Call Transcript
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: ...
Maravai LifeSciences (MRVI) Q1 2024 Earnings Call Transcript
Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Growth Opportunities
Q1 2024 Maravai LifeSciences Holdings Inc Earnings Call Transcript
Maravai LifeSciences Holdings GAAP EPS of -$0.09 misses by $0.04, revenue of $64.2M beats by $3.65M
Maravai LifeSciences Reports First Quarter 2024 Financial Results
Wall Street Analysts Are Bullish on Top Healthcare Picks
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
Should You Sell Maravai LifeSciences (MRVI)?